Form 4: Immunome Inc. Executive Philip Tsai Reports Stock Option Grant

Philip Tsai, Chief Technology Officer of Immunome Inc., reports the acquisition of stock options.

Summary

• On June 17, 2024, Philip Tsai, the Chief Technology Officer of Immunome Inc., was granted stock options to purchase 250,000 shares of Immunome Inc. common stock.
• The exercise price of the options is $13.15 per share.
• 25% of the options vest on June 17, 2025, and the remaining options vest monthly over the following three years.
• The options expire on June 16, 2034.
• Following the transaction, Tsai directly owns 250,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive's ability to contribute to the company's success. There are no explicitly negative aspects in the filing.

Positives

• The granting of stock options to a key executive like the CTO can align their interests with those of the shareholders, incentivizing them to work towards the company's success.

Future Outlook

This document does not contain any specific forward-looking statements or guidance regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. This grant is typical for a company of Immunome's size and stage.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options to incentivize their leadership teams.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for long-term incentive plans.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the executive's performance leads to company growth.
• The grant incentivizes the CTO, potentially improving employee morale and productivity.

Key Dates